The Application of Nanopore Targeted Sequencing for Pathogen Diagnosis in Bronchoalveolar Lavage Fluid of Patients with Pneumonia: a Prospective Multicenter Study.
Qinqing Lin,Yake Yao,Xi Li,Shanshan Zhang,Huimin Guo,Xiaolong Ma,Wenyu Chen,Chuhui Ru,Limin Wang,Bin Wang,Qiang Ma,Junfei Zhu,Xuemei Lin,Qi Chen,Hui Lou,Junjun Chen,Zhu Zeng,Jianying Zhou,Yan Chen,Yunsong Yu,Hua Zhou
DOI: https://doi.org/10.1080/23744235.2023.2276785
2023-01-01
Infectious Diseases
Abstract:ObjectiveTo evaluate the value of nanopore targeted sequencing in diagnosing pneumonia pathogens.MethodsThis large-scale multicentre prospective study performed in 8 hospitals across China from April to October 2022. Hospitalised patients with a diagnosis of pneumonia at admission were included. Complete clinical data were collected, and bronchoalveolar lavage fluid were obtained from each patient. These samples underwent simultaneous testing using conventional microbial testing, metagenomic next-generation sequencing, and nanopore targeted sequencing.ResultsA total of 218 patients were included. Among the 168 cases of pulmonary infection, 246 strains of pathogens were confirmed. Nanopore targeted sequencing outperformed conventional microbial testing, identifying more pathogens with a sensitivity increase of 47.9% (77.2% vs. 29.3%). Metagenomic next-generation sequencing had a sensitivity of 82.9%. Total of 70.1% patients had consistent results in both metagenomic next-generation sequencing and nanopore targeted sequencing. Nanopore targeted sequencing exhibited significantly higher sensitivity in detecting Pneumocystis jiroveci, cytomegalovirus, Mycobacterium tuberculosis, Nontuberculous mycobacteria, Streptococcus pneumoniae, and Mycoplasma pneumoniae compared to conventional microbial testing. However, metagenomic next-generation sequencing demonstrated higher sensitivity than nanopore targeted sequencing for Aspergillus (88.5% vs. 53.8%). Regarding the detection of co-infections, nanopore targeted sequencing displayed significantly higher sensitivity than conventional microbial testing (76.7% vs. 28.7%) and was on par with metagenomic next-generation sequencing (76.7% vs. 82.9%).ConclusionNanopore targeted sequencing performs equally well as metagenomic next-generation sequencing in bronchoalveolar lavage fluid for pathogen diagnosis in pneumonia, both methods showing higher sensitivity than conventional microbial testing. Nanopore targeted sequencing can be considered a reliable method for diagnosing pathogens in pneumonia.